VIVO - Meridian Bioscience hits 52-week high; stock up 36% YTD

Diagnostics and molecular reagents company Meridian Bioscience (NASDAQ:VIVO) hit a 52-week high of $28.93 on Wednesday. As of Wednesday morning, the stock is up 36% year to date. Meridian (VIVO) has benefitted from a strong demand for reagents associated with COVID-19 antigen testing, particularly during the recent Omicron wave. That prompted the company to raise its preliminary fiscal year 2022 Q2 forecast. Meridian recently said that its qPCR master mixes can be used in diagnostic tests to detect monkeypox.

For further details see:

Meridian Bioscience hits 52-week high; stock up 36% YTD